[Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) vs ado-trastuzumab emtansine (T-DM1) in subjects with HER2-positive, unresectable and/or metastatic breast cancer who previously received trastuzumab and a taxane: A phase 3, randomized trial (DESTINY-Breast03)

首页> 外文期刊>Intelligence: A Multidisciplinary Journal >[Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) vs ado-trastuzumab emtansine (T-DM1) in subjects with HER2-positive, unresectable and/or metastatic breast cancer who previously received trastuzumab and a taxane: A phase 3, randomized trial (DESTINY-Breast03)

【24h】

[Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) vs ado-trastuzumab emtansine (T-DM1) in subjects with HER2-positive, unresectable and/or metastatic breast cancer who previously received trastuzumab and a taxane: A phase 3, randomized trial (DESTINY-Breast03)

机译：[FAM-]曲妥珠单抗（T-DXD; DS-8201A）与预先接受曲妥珠单抗和紫杉烷的患者（T-DXD; DS-8201A）对受试者的ADO-TRASTUZUMAB emtansine（T-DM1）与HER2-阳性，不可切除的和/或转移性乳腺癌：阶段3 ，随机试验（Destiny-Breast03）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Intelligence: A Multidisciplinary Journal》 |2020年第2020期|共2页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类心理学;
关键词

相似文献

外文文献

1. [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) vs ado-trastuzumab emtansine (T-DM1) in subjects with HER2-positive, unresectable and/or metastatic breast cancer who previously received trastuzumab and a taxane: A phase 3, randomized trial (DESTINY-Breast03) [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：[FAM-]曲妥珠单抗（T-DXD; DS-8201A）与预先接受曲妥珠单抗和紫杉烷的患者（T-DXD; DS-8201A）对受试者的ADO-TRASTUZUMAB emtansine（T-DM1）与HER2-阳性，不可切除的和/或转移性乳腺癌：阶段3 ，随机试验（Destiny-Breast03）
2. [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) in subjects with HER2-positive metastatic breast cancer previously treated with T-DM1: A phase 2, multicenter, open-label study (DESTINY-Breast01) [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：[FAM-]曲妥珠单抗Deruxtecan（T-DXD; DS-8201A）在预先用T-DM1治疗的Her2阳性转移性乳腺癌的受试者中：2阶段，多中心，开放标签研究（Destiny-Break01）
3. A phase 1, multicenter, open-label study to assess the effect of [fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) on QTc and pharmacokinetics in subjects with HER2-expressing metastatic and/or unresectable breast cancer [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：1阶段，多中心，开放标签研究，以评估[FAM-]曲妥珠单抗甲壳（T-DXD; DS-8201A）对QTC和药代动力学的影响，所述乳腺癌的QTC和药代动力学，所述乳腺癌的QTC和药代动力学
4. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
5. A randomized controlled phase II trial of neoadjuvant ado-trastuzumab emtansine lapatinib and nab-paclitaxel versus trastuzumab pertuzumab and paclitaxel in HER2-positive breast cancer (TEAL study) [O] . Tejal A. Patel, Joe E. Ensor, Sarah L. Creamer, 2019

机译：HER2阳性乳腺癌的新辅助药物阿托曲妥珠单抗坦帕尼和纳布-紫杉醇与曲妥珠单抗帕妥珠单抗和紫杉醇的II期随机对照对照试验（TEAL研究）
6. Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD) [O] . Toshinari Yamashita, Norikazu Masuda, Shigehira Saji, 2020

机译：校正至：Trastuzumab，Pertuzumab和Eribulin甲蛋白与曲妥珠单抗，Pertuzumab和紫杉烷作为Her2阳性，局部晚期或转移性乳腺癌的一线或二线治疗：用于随机控制，非劣势的研究方案，日本第三阶段试验（JBCRG-M06 / Emerald）

[Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) vs ado-trastuzumab emtansine (T-DM1) in subjects with HER2-positive, unresectable and/or metastatic breast cancer who previously received trastuzumab and a taxane: A phase 3, randomized trial (DESTINY-Breast03)

著录项

相似文献

相关主题

期刊订阅